351. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- Author
-
Charles L. Sawyers, Ping Mu, Maxwell M. Goodrich, Zachary W. Goodrich, David W. Goodrich, Myles Brown, Eduardo Cortes Gomez, Leigh Ellis, Yanqing Wang, David P. Labbé, Sheng-Yu Ku, Henry W. Long, Bo Xu, Massimo Loda, Jianmin Wang, Spencer Rosario, and Mukund Seshadri
- Subjects
Oncology ,Male ,0301 basic medicine ,Cell Plasticity ,030232 urology & nephrology ,Retinoblastoma-Like Protein p107 ,Antiandrogen ,Epigenesis, Genetic ,Metastasis ,Mice ,Prostate cancer ,0302 clinical medicine ,Neoplasm Metastasis ,Antiandrogen Therapy ,Multidisciplinary ,biology ,Androgen Antagonists ,Neuroendocrine Tumors ,030220 oncology & carcinogenesis ,medicine.medical_specialty ,Lineage (genetic) ,medicine.drug_class ,Urology ,Adenocarcinoma ,Article ,03 medical and health sciences ,SOX2 ,Cell Line, Tumor ,Internal medicine ,medicine ,Animals ,Humans ,PTEN ,Cell Lineage ,Enhancer of Zeste Homolog 2 Protein ,business.industry ,SOXB1 Transcription Factors ,PTEN Phosphohydrolase ,Prostatic Neoplasms ,Cancer ,Neoplasms, Experimental ,medicine.disease ,Androgen receptor ,030104 developmental biology ,Drug Resistance, Neoplasm ,Mutation ,Immunology ,biology.protein ,Cancer research ,Tumor Suppressor Protein p53 ,business - Abstract
Evading cancer drugs by identity fraud Prostate cancer growth is fueled by male hormones called androgens. Drugs targeting the androgen receptor (AR) are initially efficacious, but most tumors eventually become resistant (see the Perspective by Kelly and Balk). Mu et al. found that prostate cancer cells escaped the effects of androgen deprivation therapy through a change in lineage identity. Functional loss of the tumor suppressors TP53 and RB1 promoted a shift from AR-dependent luminal epithelial cells to AR-independent basal-like cells. In related work, Ku et al. found that prostate cancer metastasis, lineage switching, and drug resistance were driven by the combined loss of the same tumor suppressors and were accompanied by increased expression of the epigenetic regulator Ezh2. Ezh2 inhibitors reversed the lineage switch and restored sensitivity to androgen deprivation therapy in experimental models. Science , this issue p. 84 , p. 78 ; see also p. 29
- Published
- 2017
- Full Text
- View/download PDF